Inflammatory markers, D-dimer, pro-thrombotic factors, and physical activity levels in patients with peripheral arterial disease

Vascular Medicine

Volumn 9, Issue 2, 2004, Pages 107-115

  McDermott, Mary McGrae ^a   Greenland, Philip ^a   Guralnik, Jack M ^b   Ferrucci, Luigi ^b   Green, David ^a   Liu, Kiang ^a   Criqui, Michael H ^c   Schneider, Joseph R ^a,d   Chan, Cheeling ^a   Ridker, Paul ^e   Pearce, William H ^a   Martin, Gary ^a   Clark, Elizabeth ^f   Taylor, Lloyd ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EVANSTON HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Saint Joseph Hospital   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

C reactive protein; D dimer; Intermittent claudication; Peripheral arterial disease; Physical activity; Physical functioning

Indexed keywords

BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SERUM AMYLOID A; TISSUE PLASMINOGEN ACTIVATOR;

ACCELEROMETER; ADULT; AGE; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG USE; FEMALE; HEMOSTASIS; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SEX; SMOKING;

ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; MOTOR ACTIVITY; PERIPHERAL VASCULAR DISEASES; THROMBOPLASTIN;

EID: 6444223265     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm525oa     Document Type: Article

References (55)

1. Ridker PM, Cushman M, Stampfer MJ, Tracey RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-79.
2. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
3. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
4. Biasucci LM, Vitelli A, Liuzzo G et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-77.
5. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FGR, Lowe GDO. Haemostatic factors and prediction of ischemic heart disease and stroke in claudicants. B J Haematol 1998; 100: 758-63.
6. Ferrucci L, Harris TB, Guralnik JM et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47: 639-46.
7. Cohen HJ, Pieper CF, Harris T, Rao KMK, Currie MS. The association of plasma IL-6 with functional disability in community-dwelling elderly. J Gerontol Med Sci 1997; 52A: M201-208.
8. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722-27.
9. McDermott MM, Greenland P, Liu K et al. The ankle brachial index as a measure of leg functioning and physical activity in peripheral arterial disease: The Walking And Leg Circulation Study. Ann Intern Med 2002; 136: 873-83.
10. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-86.
11. Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995; 74: 828-32.
12. Van der Born JG, Bots ML, Haverkate F et al. Activation products of the haemostatic system in coronary, cerebrovascular, and peripheral arterial disease. Thromb Haemost 2001; 85: 234-39.
13. McDermott MM, Greenland P, Green D et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003; 107 191-98.
14. Mitch WE, Goldberg AL. Mechanism of muscle wasting: the role of ubiquitin-proteasome pathway. N Engl J Med 1997; 335: 1897-905.
15. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994; 205: 182-85.
16. Roubenoff R. Inflammatory and hormonal mediators of cachexia. J Nutr 1997; 127: 1014-16.
17. Ferrucci L, Penninx BW, Volpato S et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 2002; 12 1947-54.
18. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product d-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-26.
19. Rao KMK, Pieper CS, Currie MS, Cohen HJ. Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 1994; 102: 802-805.
20. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002; 121: 1262-68.
21. Edgington TS, Curtiss LK, Plow EF. A linkage between the haemostatic and immune systems embodied in the fibrinolytic release of lymphocytic suppressive peptides. J Immunol 1985; 134: 471-77.
22. Stratton JR, Chandler WL, Schwartz RS et al. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 1991; 83: 1692-97.
23. Chandler WL, Schwartz RS, Stratton JR et al. Effects of endurance training on the circadian rhythm of fibrinolysis in men and women. Med Sci Sports Exerc 1996; 28: 647-55.
24. Paramo JA, Olavide I, Barba J et al. Long-term cardiac rehabilitation program favorably influences fibrinolysis and lipid concentrations in acute myocardial infarction. Haematologica 1998; 83: 519-24.
25. Gardner AW, Killewich LA. Association between physical activity and endogenous fibrinolysis in peripheral arterial disease: a cross-sectional study. Angiology 2002; 53: 367-74.
26. Mustonen P, Lepantalo M, Lassila R. Physical exertion induces thrombin formation and fibrin degradation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 244-49.
27. McDermott MM, Greenland P, Liu K et al. Leg symptoms commonly reported by men and women with lower extremity peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286: 1599-606.
28. McDermott MM, Criqui MH, Liu K et al. The lower ankle brachial index calculated by averaging the dorsalis pedis and posterior tibial arterial pressures is most closely associated with leg functioning in peripheral arterial disease. J Vasc Surg 2000; 32: 1164-71.
29. Ledue TB, Weiner DL, Sipe JD et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem 1998; 35: 745-53.
30. Allain CC, Poon LS, Chan CSG et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-75.
31. Sugiuchi H, Ugi Y, Okabe H et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated a-cyclodextrin. Clin Chem 1995; 41: 717-23.
32. McDermott MM, Ohlmiller SM, Liu K et al. Gait alterations associated with walking impairment in people with peripheral arterial disease with and without intermittent claudication. J Am Geriatr Soc 2001; 49: 747-54.
33. Guralnik JM, Fried LP, Simonsick EM, Kaspar JD, Lafferty ME. The Women's Health and Aging Study: health and social characteristics of older women with disability. Bethesda, MD: National Institute on Aging, 1995: NIH publication No. 95-4009, Appendix E.
34. Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 2002; 39: 109-12.
35. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12 157-61.
36. Pizzo SV, Petruska DB, Domain KA, Soong SJ, Fuchs HE. Releasable vascular plasminogen activator and thrombotic strokes. Am J Med 1985; 79: 407-11.
37. Lapolla A, Piarulli F, Sartore G et al. Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 2003; 89: 91-96.
38. Rydzewski A, Sakata K, Kobayashi A et al. Changes in plasminogen activator inhibitor-1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease. Haemostasis 1990; 20: 305-12.
39. Walston J, McBurnie MA, Newman A et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities. Arch Intern Med 2002; 162: 2333-41.
40. Kado DM, Bucur A, Selhub J, Rowe JW, Seeman T. Homocysteine levels and decline in physical function: MacArthur studies of successful aging. Am J Med 2002; 113: 537-42.
41. Gauldie J, Northemann W, Fey GHO. IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. J Immunol 1990; 144: 3804-808.
42. Charters Y, Grimble RF. Effect of recombinant human tumor necrosis factor alpha on protein synthesis in liver, skeletal muscle and skin of rats. Biochem J 1989; 258: 493-97.
43. Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 1991; 260: E727-730.
44. Tayek JA. Effects of tumor necrosis factor alpha in skeletal muscle amino acid metabolism studies in-vivo. J Am Coll Nutr 1996; 15: 164-68.
45. Koenig W, Ernst E. Exercise and thrombosis. Coron Artery Dis 2000; 11: 123-27.
46. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
47. Connolly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen, and factor VII activity. Br Heart J 1992; 6: 351-54.
48. Elwood PC, Yarnell JWG, Pickering J, Fehily AM, O'Brien JR. Exercise, fibrinogen and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study. Br Heart J 1993; 69 183-87.
49. Lakka TA, Salonen JT. Moderate to high intensity conditioning leisure-time physical activity and high cardiorespiratory fitness are associated with reduced plasma fibrinogen in eastern Finnish men. J Clin Epidemiol 1993; 46: 1119-27.
50. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001; 153: 242-50.
51. Wosornu D, Allardyce W, Ballantyne D, Tansey P. Influence of power and aerobic exercise training on haemostatic factors after coronary artery surgery. Br Heart J 1992; 68: 181-82.
52. Stratton JR, Chandler WL, Schwartz RS et al. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 1991; 83: 1692-97.
53. 453-A polymorphism of the β-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996; 16: 386-91.
54. Prisco D, Paniccia R, Guarnaccia V et al. Thrombin generation after physical exercise. Thromb Res 1993; 69: 159-64.
55. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ 1979; i: 153-56.